CXCL family of chemokine: Clinical perspective in colorectal cancer
DOI:
https://doi.org/10.63626/q6ac7p23Keywords:
Serum levels , Expression , Chemokine, Colorectal cancerAbstract
Background: Chemokine are small proteins which play a critical role in colorectal pathophysiology by stimulating inflammation, influencing angiogenesis and movement of immune cells. Recent research has emphasized the possible role of CXC chemokine family in influencing cancer development. In this study, focus was to investigate the CXC chemokines as potential biomarkers in colorectal cancer by comparing their levels in primary phases.
Methods: This comparative cross-sectional study was conducted while using serum samples of colorectal cancer patients (stage II & III) and healthy controls. The circulatory levels of CXCL chemokines were quantified by using enzyme-linked immunosorbent assay (ELISA) and differences between chemokine levels of colorectal cancer patients and healthy controls were analyzed using an independent t-test via the latest version of SPSS.
Results: The study findings showed that concentrations of CXCL1, CXCL9, and CXCL11 chemokine were raised considerably with colorectal cancer progression, particularly in stage III, indicating their involvement in cancer progression. CXCL10 and CXCL11 concentrations were found to be significantly altered between the two stages of colorectal cancer (p<0.05).
Conclusion: CXCL levels de-regulate in colorectal cancer and may serve as biomarkers and therapeutic targets.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 This is an open access journal, and published articles are distributed under the terms of Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This work is licensed under a Creative Commons Attribution 4.0 International License.
